The aim of this study is to evaluate the bio-clinical effects of sacubitril/valsartan combination in treatment of patients with Congestive heart failure. Moreover, the investigators aim to evaluate side effects of this combination. \- The following parameters were determined at baseline and at end of the study at 6 months of the beginning. 1. New York Heart Association (NYHA) Class. 2. Frequency of hospitalization by acute exacerbation of CHF 3. NT-ProBNP 4. Left ventricular systolic function by Echocardiography Moreover, the side effects of the drugs used during study was assessed by 1. Renal function (Serum creatinine) was performed every month till the end of the study. 2. Serum electrolytes (Potassium and Sodium) was performed every month till the end of the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
Wadi El-Neel Hospital
Cairo, Egypt
change in NTproBNP plasma concentration
NTproBNP is a Biomarker used to assess severity of congestive heart failure)
Time frame: at baseline
change in NTproBNP plasma concentration
NTproBNP is a Biomarker used to assess severity of congestive heart failure)
Time frame: at 6 months
severity of congestive heart failure.
Ejection fraction
Time frame: at baseline
severity of congestive heart failure.
Ejection fraction
Time frame: at 6 months
change in plasma potassium concentration
plasma potassium (intracellular cation) concentration used to evaluate Sacubitril-Valsartan
Time frame: every month, up to 6 months
change in serum sodium concentration
serum sodium (extracellular cation) concentration used to evaluate Sacubitril-Valsartan
Time frame: every month, up to 6 months
change in serum creatinine
serum creatinine which is a byproduct of muscle protein metabolism is used to evaluate Sacubitril-Valsartan
Time frame: every month, up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.